These treatments are uncomfortable and expensive, so it is welcome news that several longer -
lasting clotting factors have been developed.
Not exact matches
In Madrid
last week, Amit Nathwani of the Royal Free NHS Trust in London announced that six people treated for haemophilia using AAV in early 2011 are still producing the blood
clotting factor they previously lacked.
For now, improvement in treatment lies in the emergence of new, longer -
lasting replacements for the blood -
clotting factors missing from the blood of people with the condition.
To create a longer -
lasting preventive therapy for severe hemophilia A-associated bleeding, a group of Japanese researchers launched a first - in - human Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACE910, a bispecific antibody that mimics FVIII and works with other
clotting factors to make the blood
clot properly.